IRIX Stock - IRIDEX Corporation
Unlock GoAI Insights for IRIX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $48.67M | $51.87M | $56.97M | $53.90M | $36.35M |
| Gross Profit | $19.50M | $21.81M | $25.37M | $22.83M | $15.56M |
| Gross Margin | 40.1% | 42.0% | 44.5% | 42.4% | 42.8% |
| Operating Income | $-8,302,000 | $-10,007,000 | $-7,542,000 | $-7,533,000 | $-6,583,000 |
| Net Income | $-8,910,000 | $-9,570,000 | $-7,547,000 | $-5,225,000 | $-6,329,000 |
| Net Margin | -18.3% | -18.5% | -13.2% | -9.7% | -17.4% |
| EPS | $-0.54 | $-0.59 | $-0.47 | $-0.34 | $-0.46 |
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
Visit WebsiteEarnings History & Surprises
IRIXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q4 2025 | Nov 11, 2025 | $-0.06 | $-0.09 | -50.0% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.09 | $-0.06 | +33.3% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.10 | $-0.10 | 0.0% | = MET |
Q1 2025 | Mar 27, 2025 | $-0.05 | $-0.05 | 0.0% | = MET |
Q4 2024 | Nov 12, 2024 | $-0.09 | $-0.12 | -33.3% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.12 | $-0.16 | -33.3% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-0.12 | $-0.21 | -75.0% | ✗ MISS |
Q1 2024 | Mar 26, 2024 | $-0.05 | $-0.18 | -260.0% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.13 | $-0.11 | +15.4% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.11 | $-0.17 | -54.5% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.12 | $-0.13 | -8.3% | ✗ MISS |
Q1 2023 | Mar 9, 2023 | $-0.11 | $-0.07 | +36.4% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.15 | $-0.11 | +26.7% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-0.16 | $-0.14 | +12.5% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.16 | $-0.15 | +6.3% | ✓ BEAT |
Q1 2022 | Mar 10, 2022 | $-0.11 | $-0.15 | -36.4% | ✗ MISS |
Q4 2021 | Nov 11, 2021 | $-0.15 | $-0.14 | +6.7% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-0.16 | $-0.09 | +43.8% | ✓ BEAT |
Q2 2021 | May 11, 2021 | $-0.14 | $-0.14 | 0.0% | = MET |
Latest News
New Study Shows Iridex Laser Treatment Safely Lowers Eye Pressure for Glaucoma Patients
📈 PositiveIridex Announces Newly Published Study In Translational Vision Science & Technology Examining Thermal Dynamics Of Transscleral Laser Treatments For Glaucoma
📈 PositiveIRIDEX shares are trading lower. The company reported Q3 financial results.
📉 NegativeIRIDEX shares are trading lower. The company reported Q3 financial results.
📉 NegativeIridex Q3 EPS $(0.09) Up From $(0.12) YoY, Sales $12.484M Up From $11.581M YoY
📈 PositiveIridex Corporation Receives Notification Of Nasdaq Listing Compliance
➖ NeutralIridex Reports 7 Percent Q2 Revenue Gain
📈 PositiveFrequently Asked Questions about IRIX
What is IRIX's current stock price?
What is the analyst price target for IRIX?
What sector is IRIDEX Corporation in?
What is IRIX's market cap?
Does IRIX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to IRIX for comparison